Related Experiment Video
Updated: Jul 6, 2026
05:56
Exploring Caspase Mutations and Post-Translational Modification by Molecular Modeling Approaches
Published on: October 13, 2022
Caspase polymorphisms and genetic susceptibility to multiple myeloma
H Dean Hosgood1, Dalsu Baris, Yawei Zhang
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7240, USA. hosgoodd@mail.nih.gov
Hematological Oncology
|April 3, 2008
Summary
Genetic variations in caspase genes may influence multiple myeloma risk. Specific single nucleotide polymorphisms (SNPs) in CASP3 and CASP9 show a decreased risk for this hematological malignancy.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Multiple myeloma is a hematological malignancy driven by plasma cell expansion.
- The precise causes of multiple myeloma remain largely unknown.
- Apoptosis evasion is crucial for tumor formation, with caspase cascades regulating this process.
Purpose of the Study:
- To investigate the association between specific single nucleotide polymorphisms (SNPs) in four caspase genes and multiple myeloma risk.
- To explore the role of genetic variations in apoptosis-related genes in the etiology of multiple myeloma.
Main Methods:
- A population-based case-control study was conducted with 128 female multiple myeloma cases and 516 controls in Connecticut.
- Five single nucleotide polymorphisms (SNPs) in CASP3, CASP8, CASP9, and CASP10 genes were analyzed.
- Genotype frequencies were compared between cases and controls to calculate odds ratios (OR) and confidence intervals (CI).
Main Results:
- The CC genotype of CASP3 Ex8 + 567 T > C was associated with a five-fold decreased risk of multiple myeloma (OR = 0.2, 95% CI = 0.0-1.0).
- The AG and AA genotypes of CASP9 Ex5 + 32 G > A also showed a decreased risk (OR(AG) = 0.8, 95% CI = 0.5-1.3; OR(AA) = 0.5, 95% CI = 0.3-0.9; p-trend = 0.02).
- No prior studies have directly linked caspase genes to multiple myeloma, though associations exist with other cancers.
Conclusions:
- Genetic variations in CASP3 and CASP9 may confer a protective effect against multiple myeloma.
- These findings suggest that genetic variation in caspase genes could play a significant role in the development of multiple myeloma.
- Further research is warranted to elucidate the mechanisms underlying these protective associations.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Caspases
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...